Lucid Diagnostics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), has announced its participation in two upcoming investor conferences. The company will attend the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 12-13, 2024. Additionally, Lucid will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024, at 1:30 PM ET.

Investors can access the live and archived webcast of the Canaccord Genuity fireside chat through the provided link or by visiting the Investor Relations Section of the Lucid Diagnostics website. A replay of the webcast will be available on the website for 30 days following the live broadcast.

NEW YORK, Aug. 5, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the following upcoming investor conferences:

• 9^th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
  • Dates: August 12-13, 2024

• Canaccord Genuity 44^th Annual Growth Conference
  • Fireside Chat: Tuesday, August 13, 2024, at 1:30 PM ET

The live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking here or by visiting the Investor Relations Section of the Lucid Diagnostics website.  A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast.

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard^® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck^® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-participate-in-upcoming-investor-conferences-302214081.html

SOURCE Lucid Diagnostics

FAQ

What investor conferences will Lucid Diagnostics (LUCD) participate in during August 2024?

Lucid Diagnostics will participate in the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 12-13, 2024, and the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024.

When is Lucid Diagnostics' (LUCD) fireside chat at the Canaccord Genuity conference?

Lucid Diagnostics' fireside chat at the Canaccord Genuity 44th Annual Growth Conference is scheduled for Tuesday, August 13, 2024, at 1:30 PM ET.

How can investors access Lucid Diagnostics' (LUCD) fireside chat webcast?

Investors can access the live and archived webcast of Lucid Diagnostics' fireside chat through a provided link or by visiting the Investor Relations Section of the Lucid Diagnostics website.

How long will the replay of Lucid Diagnostics' (LUCD) Canaccord Genuity fireside chat be available?

A replay of Lucid Diagnostics' Canaccord Genuity fireside chat webcast will be available on the company's website for 30 days following the conclusion of the live broadcast.